Scout Investments Lowers stake in ABIOMED (ABMD)

ABIOMED (ABMD) : Scout Investments reduced its stake in ABIOMED by 18.83% during the most recent quarter end. The investment management company now holds a total of 269,067 shares of ABIOMED which is valued at $33,388,524 after selling 62,436 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.ABIOMED makes up approximately 0.89% of Scout Investments’s portfolio.

Other Hedge Funds, Including , William Blair Investment Management boosted its stake in ABMD in the latest quarter, The investment management firm added 415 additional shares and now holds a total of 813,371 shares of ABIOMED which is valued at $100,931,207. ABIOMED makes up approx 0.37% of William Blair Investment Management’s portfolio.Lebenthal Lisanti Capital Growth boosted its stake in ABMD in the latest quarter, The investment management firm added 1,945 additional shares and now holds a total of 4,675 shares of ABIOMED which is valued at $562,169. ABIOMED makes up approx 0.78% of Lebenthal Lisanti Capital Growth’s portfolio.State Treasurer State Of Michigan boosted its stake in ABMD in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 15,800 shares of ABIOMED which is valued at $1,873,564. ABIOMED makes up approx 0.01% of State Treasurer State Of Michigan’s portfolio.Public Employees Retirement Association Of Colorado boosted its stake in ABMD in the latest quarter, The investment management firm added 786 additional shares and now holds a total of 190,106 shares of ABIOMED which is valued at $22,426,805. ABIOMED makes up approx 0.18% of Public Employees Retirement Association Of Colorado’s portfolio.

ABIOMED closed down -0.3 points or -0.24% at $123.39 with 3,14,061 shares getting traded on Monday. Post opening the session at $123.81, the shares hit an intraday low of $123.22 and an intraday high of $124.43 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Leave a Reply

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.